Smile card: a computerized data card for multiple sclerosis patients

Smile card: a computerized data card for multiple sclerosis patient

Epidemiologia delle malattie del neurone di moto.

Revisione critica della letteratura scientifica che riguarda gli studi descrittivi, analitici e prognostici e terapeutici relativi alle malattie del neurone di moto, alla sclerosi laterale amiotrofica in particolare

Epidemiologia del morbo di Parkinson

Revisione critica delle ricerche neuroepidemiologiche sulla malattia di Parkinson e i parkinsonismi: studi di incidenza, prevalenza, mortalità, sopravvivenza, fattori di rischio genetici e ambientali, approcci terapeutici

Clinical infections and multiple sclerosis: contribution from analytical epidemiology

--

Principi e metodi della neuropidemioloia clinica

Il Manuale sviluppa principi generali dell'epidemiologia descrittiva e analitica. Successivamente tratta specificamente la revisione degli studi epidemiologici disponibili nel mondo relativamente alle malattie neurologich

the use of laboratory test in the early diagnosis of multiple sclerosis

Laboratoristic tests in the diagnosis of multiple sclerosi

Subarachnoid hemorrage presenting as chest pain

We describe a patient with spinal subarachnoid hematoma whose clinical presentation with sudden acute chest pain without any neurologic sign at onset prompted the initial diagnostic suspicion of an acute vascular emergency

Selected reviews common childhood and adolescent infections and multiple sclerosis

--

Oslo international think-thank on multiple sclerosis epidemiology

Methodological approach for analytical studies on multiple sclerosis, according to the results of the Oslo International Think Tank on Multiple Sclerosis Epidemiology

Azathioprine therapy for Multiple Sclerosis

We focus on pharmacokinetic and pharmacodynamic properties of azathioprine, and on the efficacy and safety of the drug in multiple sclerosis patients. Azathioprine (AZA) is an immunosuppressive drug widely prescribed for the treatment of multiple sclerosis until the advent of interferon beta and glatiramer acetate. Data on its efficacy derive from old and often small clinical trials. The available results suggest that AZA reduces relapse rate, with a slight effect on disability progression. More recently, small studies detected a significant reduction in enhancing MRI lesions in patients treated with AZA. Several trials have suggested that the drug might be effective, at least in the short term, as an add-on treatment in patients breaking through monotherapy with conventional first-line drugs. Concerns about safety, mainly a possible increased risk of malignancy, have been raised. A review of the literature suggests that the safety profile of AZA is a cceptable, and that the risk of cancer does not significantly increase provided the cumulative dose is less than 300 g. Further large and well-conducted studies are needed to confirm the efficacy of the drug in monotherapy or in combination